Non-invasive shockwave therapy that accelerates healing and boosts practice success—trusted by top providers nationwide. This page is for providers.
If you are a patient seeking treatment please visit https://softwavetrt.com/providers/ SoftWave TRT, LLC is a medical technology company that is developing advanced solutions specializing in shockwave therapy for better patient healing.
Founded in 2004 and headquartered in Alpharetta, GA, SoftWave TRT is committed to the scientific advancement of tissue healing and regeneration and the development of the most effective innovations to improve the quality of lives globally. German-engineered with superior quality, it is used worldwide in the healthcare fields of orthopedics, traumatology, wound care, aesthetics, and urology. SoftWave technology is trusted by the top major medical research centers in the U.S. and worldwide, with over 300 published studies of the technology supporting its effectiveness. It has a strong international presence with its German manufacturing partner and is internationally recognized by the International Society for Medical Shockwave Technology (ISMST).
10/02/2025
📢 The 2025 AUA Guidelines are here!
For men living with chronic pelvic pain, the new guideline emphasizes multimodal, non-invasive care. One of the most exciting updates? Shockwave therapy (low-intensity ESWT) received a high level of evidence rating.
Studies show potential benefits in:
✅ Reducing pain
✅ Improving urinary function
✅ Supporting sexual health
SoftWave offers providers a safe, non-invasive treatment option that aligns with the latest recommendations.
2025 AUA Guidelines on Male Chronic Pelvic Pain highlight multimodal, non-invasive care. Shockwave therapy earns high evidence rating.
10/02/2025
Why mask symptoms when you can heal where it matters most — at the cellular level? 🔬
10/01/2025
The 27th ISMST Congress in Bogotá was an inspiring showcase of where shockwave medicine is headed—and our team was proud to be there.🇨🇴
Key takeaways from this year’s event included:
✔️Immersive VR technology that redefined how complex shockwave concepts and techniques can be taught and experienced.
📑 A wide range of new research and abstracts, expanding the evidence base and reaffirming the role of shockwave therapy across disciplines.
🫀 A fascinating case report presented by Dr. John David Mullins and Dr. Wolfgang Schaden: Self-Administered Acoustic Shock Wave Therapy in Managing Ventricular Ectopy in HFrEF. This 1-patient study opens an important conversation on novel applications of acoustic wave therapy in cardiac health.
From groundbreaking tools to bold new research, Bogotá highlighted how collaboration and innovation are accelerating the future of shockwave therapy. We left energized, connected, and more committed than ever to driving this field forward.💥
09/25/2025
SoftWave is the only true broad-focused shockwave therapy. That means deeper reach, wider coverage, and better outcomes—helping you treat more conditions and more patients with confidence.
09/23/2025
Go beyond the surface. SoftWave doesn’t just mask symptoms—it activates natural healing where real change happens: at the cellular level. Backed by research and trusted by providers nationwide, SoftWave is redefining what recovery looks like.
09/18/2025
When you choose SoftWave, you’re choosing technology that’s researched, trusted, and effective—with results you can count on and patients who feel the difference.
09/14/2025
When every week on the sidelines matters, providers choose SoftWave. Backed by science. Trusted by pros. 💪
09/11/2025
Can broad-focused ESWT help heal diabetic foot ulcers?
At SAWC Fall 2025, Richard Kaufman, DPM, FACFAS, CWSP shared a case series using broad-focused extracorporeal shockwave therapy (ESWT) on chronic DFUs—showing faster healing, pain reduction, and no adverse events.
What stood out:
✅ 9 of 10 patients healed within 12 weeks
✅ Avg. healing time: 9.6 weeks
✅ 60% reduction in pain
Dr. Kaufman believes broad-focused ESWT treats larger wound areas more comfortably and efficiently than other approaches—potentially revolutionizing DFU care.
Clinicians, we want to hear from you.
What’s the #1 reason you chose SoftWave for your practice?
Drop your answer in the comments ⬇️
09/02/2025
From pro athletes to family care — SoftWave delivers results that matter. 💪
08/21/2025
From a routine surgery… to facing the devastating possibility of amputation.
Former football coach Phil Wilks was told he might lose his leg. That’s when Dr. John David Mullins of Piedmont and Dr. Marvin Royster of Peachtree Orthopedics turned to innovation. With the help of SoftWave Therapy, they were able to save his leg—and give him a second chance at mobility and life.
This isn’t just one man’s story. It’s proof that advanced, non-invasive technologies like SoftWave are transforming outcomes in hospitals and clinics across the country.
When former coach Phil Wilks faced the possibility of losing his leg, Dr. John David Mullins (Piedmont) and Dr. Marvin Royster (Peachtree Orthopedics) turned to innovation. With the help of SoftWave Therapy, they saved his leg—and his future.
Be the first to know and let us send you an email when SoftWave TRT posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.
Tissue Regeneration Technologies (TRT) is a worldwide leader in medical shockwave technology. TRT manufactures and distributes various shockwave (ESWT) devices including the unfocused LithoGold lithotripter, UroGold, DermaGold, and OrthoGold. These medical devices are used in Urology, Orthopedics, Sports Medicine, Wound care, and Cardiology. In 2006, TRT has proven that its patented SoftWave technology has a strong regenerative effect on tissue including skin, bones, nerves, and heart.
The patented softwave technology uses various lens configurations to produce pressure waves. These waves have a characteristic pressure profile of short rise-times reaching high amplitudes (comparable to a sonic boom). The pressure waves can be shaped through a reflector, which enables the transmission of either highly-focused Shockwaves for use on urinary stones or non-union fractures, or soft-focused pressure waves (i.e., SoftWaves) for most soft tissue indications.
TRT’s patented SoftWave technology is distinguished from competitors’ shockwave technology in that TRT uses a patented parabolic (as opposed to an ellipsoid) reflector in the therapy head, which allows delivery of unfocused waves of acoustic energy over a broad target area. TRT’s SoftWave technology generates less pain, has a higher efficacy rate, and has a lower re-treatment rate than competitors’ high-energy, focused shockwave systems. TRT is the first company to discover that “softwaves” have the same or better clinical benefit as high-energy focused Shockwaves for most medical conditions. Following this discovery, TRT further developed the idea into a useful format, and secured patents protecting its inventions.
The advantages of SoftWave technology include the following benefits: (1) treatments do not require anesthesia; (2) larger surfaces, such as wounds, can be treated faster and easier than with competing shockwave devices.
TRT currently has product lines developed for the treatment of six distinct areas of care:
LithoGold – Lithotripsy and urology indications
OrthoGold – Orthopedic indications
DermaGold – Wound care indications
CardioGold – Cardiac and vascular indications
VetGold – Veterinary indications
UroGold – Urologic indications
The OrthoGold has been FDA cleared for connective tissue activation and registered for increased blood flow and pain relief. The DermaGold has been FDA cleared to treat diabetic ulcers.
